Selected article for: "cross sera reactivity and sera reactivity"

Author: Takada, Ayato
Title: Filovirus Tropism: Cellular Molecules for Viral Entry
  • Document date: 2012_2_6
  • ID: 0j3efvfe_27
    Snippet: By using GP-specific monoclonal antibodies, several epitopes recognized by ADE antibodies were identified and these epitopes were mostly located in the MLR of the GP1 subunit (Takada et al., 2007; Nakayama et al., 2011) . It should be noted that neutralizing antibodies appear to recognize different epitopes that are not located on the MLR (Takada et al., 2003b; Lee et al., 2008) . As reflected by the high variability of the MLR amino acid sequenc.....
    Document: By using GP-specific monoclonal antibodies, several epitopes recognized by ADE antibodies were identified and these epitopes were mostly located in the MLR of the GP1 subunit (Takada et al., 2007; Nakayama et al., 2011) . It should be noted that neutralizing antibodies appear to recognize different epitopes that are not located on the MLR (Takada et al., 2003b; Lee et al., 2008) . As reflected by the high variability of the MLR amino acid sequences and limited overall cross-reactivity of anti-sera among filovirus species (i.e., ZEBOV, SEBOV, CIEBOV, BEBOV, REBOV, and MARV), ADE activities of the anti-sera to GP are virus-species-specific (Takada et al., , 2007 Nakayama et al., 2010) . Interestingly, potential viral pathogenicity is correlated with the ability to induce ADE antibodies, suggesting the possible contribution of ADE to different pathogenicity between filoviruses Nakayama et al., 2011) . More importantly, the demonstration of ADE of filovirus infection raises fundamental questions about the development of GP-based vaccines and the use of anti-GP antibodies for passive immunization.

    Search related documents:
    Co phrase search for related documents
    • ADE antibody and amino acid: 1, 2, 3, 4, 5, 6, 7
    • ADE antibody and amino acid sequence: 1
    • ADE antibody and different epitope: 1
    • ADE antibody and filovirus infection: 1
    • ADE antibody and monoclonal antibody: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15
    • ADE antibody and neutralize antibody: 1, 2
    • ADE antibody and passive immunization: 1, 2